Patents Examined by Lakia J Jackson-Tongue
-
Patent number: 11851643Abstract: A selective microbial detection device and methods of use are provided. The device includes a water-proof pouch that includes a first wall portion, a second wall portion, and a porous membrane filter disposed in the pouch between the first and second wall portions. The filter membrane divides the pouch into first and second compartments. The microbial detection device also includes an effective amount of a dry nutrient disposed in the first compartment, which contains sodium lauryl sulfate in an amount of 1.75 milligrams or greater per twelve square inches of the first wall portion. A dry, cold water-soluble gelling agent is adhered to the pouch in the first compartment and an absorbent pad is disposed in the second compartment. A sealable sample port provides access to deposit a liquid into the first compartment.Type: GrantFiled: May 2, 2019Date of Patent: December 26, 2023Assignee: 3M Innovative Properties CompanyInventors: Alexi J. Young, Evan D. Brutinel, Patrick A. Mach, Adam J. Stanenas
-
Patent number: 11839651Abstract: Compositions capable of enhancing and/or eliciting an immune response in a subject and methods of using the compositions. The compositions are capable of enhancing an IgA immune response and/or an IgG immune response and comprise an agent capable of reducing the level of binding of ATP to a P2X7 receptor to a subject. The compositions are for oral administration.Type: GrantFiled: December 21, 2016Date of Patent: December 12, 2023Assignee: INSTITUTE FOR RESEARCH IN BIO-MEDICINEInventors: Fabio Grassi, Michele Proietti
-
Patent number: 11833116Abstract: The present invention discloses yeast powder rich in nicotinamide mononucleotide, a preparation method and uses thereof. The preparation method includes: preparing a first medium, a second medium, and a third medium; inoculating the first medium with yeast for fermentation to obtain a first fermentation broth; inoculating the second medium with the first fermentation broth for fermentation to obtain a second fermentation broth; inoculating the third medium with the second fermentation broth for fermentation to obtain a third fermentation broth; centrifuging the third fermentation broth to obtain a fermented product; and drying the fermented product to obtain the yeast powder. Components of the first medium, the second medium and the third medium include nicotinamide, tryptophan and niacin. The content of nicotinamide mononucleotide in the yeast powder is at least 5000 ppm.Type: GrantFiled: August 25, 2021Date of Patent: December 5, 2023Assignee: TCI CO., LTD.Inventors: Yung-Hsiang Lin, Pei-Yi Wu
-
Patent number: 11828762Abstract: The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.Type: GrantFiled: November 12, 2020Date of Patent: November 28, 2023Assignee: Serimmune Inc.Inventors: Patrick Sean Daugherty, Kathryn Vinaya Louise Kamath, Jack Ryan Reifert
-
Patent number: 11820798Abstract: A method for increase the presentation of ETEC CS6 antigen on a cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.Type: GrantFiled: November 25, 2020Date of Patent: November 21, 2023Assignee: SCANDINAVIAN BIOPHARMA HOLDING ABInventors: Nils Carlin, Ann-Mari Svennerholm, Joshua Tobias
-
Patent number: 11801290Abstract: Compositions and methods for preventing, treating and detecting leprosy are disclosed. The compositions generally comprise polypeptides comprising one or more Mycobacterium leprae antigens as well as polynucleotides encoding such polypeptides.Type: GrantFiled: September 15, 2017Date of Patent: October 31, 2023Assignee: ACCESS TO ADVANCED HEALTH INSTITUTEInventors: Steven G. Reed, Malcolm S. Duthie
-
Patent number: 11788085Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.Type: GrantFiled: May 19, 2022Date of Patent: October 17, 2023Assignee: SNIPR Biome ApSInventors: Morten Sommer, Virginia Martinez, Eric Van Der Helm, Jakob Krause Haaber, Ana De Santiago Torio, Christian Grøndahl, Jasper Clube
-
Patent number: 11782060Abstract: A system and method for detecting status of a health condition in a single-step process includes: a signal output device including a) a loading zone; b) a reaction zone fluidly coupled to the loading zone and including one or more reaction substances conjugated to labels, configured to enable detection of target material associated with the health condition; c) a testing zone fluidly coupled to the reaction zone and including one or more testing substances corresponding to the target material; and d) a control zone including a control substance retained at the control zone. The system and methods can be adapted for assessment of sexual health of one or more subjects, in relation to pregnancy, fertility, and/or sexually transmitted infections caused by one or more agents including, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Treponema pallidum, Gardnerella vaginitis, human immunodeficiency virus, human papillomavirus infection, Hepatitis B, and herpes simplex virus.Type: GrantFiled: August 21, 2020Date of Patent: October 10, 2023Assignee: Simple HealthKit, Inc.Inventors: Sheena Ruby Menezes, Jerzy Majka, Linus Ryan Aranha, Quynh Nga Thi Le
-
Patent number: 11779612Abstract: Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella or modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin? and/or pagP?. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd?, purI? and msbB?.Type: GrantFiled: July 23, 2019Date of Patent: October 10, 2023Assignee: ACTYM THERAPEUTICS, INC.Inventors: Christopher D. Thanos, Laura Hix Glickman, Justin Skoble, Alexandre Charles Michel Iannello
-
Patent number: 11771065Abstract: Formulations for promoting honeybee health include an aqueous solution having an organic acid, one or more buffering agents, one or more coloring dyes, and one or more strains of probiotic bacteria. The formulations can be in the form of syrup additives or sprays. The formulations can have additional active ingredients, inert ingredients, or both.Type: GrantFiled: August 18, 2016Date of Patent: October 3, 2023Assignee: API HOLDINGS, LLCInventor: Justin Jay Brown
-
Patent number: 11771723Abstract: Bifidobacterium longum strain NCIMB 41676 is useful for improving or sustaining vitality and/or reducing mental fatigue in stressful situations.Type: GrantFiled: January 29, 2019Date of Patent: October 3, 2023Assignee: PrecisionBiotics Group LimitedInventors: Eileen Frances Murphy, Paul Enck, Christoph Braun, Huiying Wang
-
Patent number: 11766455Abstract: This disclosure is directed to a pharmaceutical composition comprises tumor inhibiting cells (TICs) and a method for producing the TICs. The tumor inhibiting cells can be derived from immune cells including T cells, NK cells, or a combination thereof, modified to have inactivated Cbl-b gene alleles and free from Cbl-b bio-function (Cbl-b?/? TICs). The Cbl-b?/? TICs are free from deoxyribonucleic acids exogenous to the immune cells. The immune cells can be isolated using a portable cell isolation and modification device. This disclosure is further directed to a method for treating tumorous conditions in subjects. The pharmaceutical composition can provide a subject-specific tumor treatment.Type: GrantFiled: December 14, 2018Date of Patent: September 26, 2023Assignees: EZY Biotech LLC, Adaerata, Limited PatnershipInventors: Hua Gu, Gang G Xu, Adeline Gadzinski, Haijun Tong
-
Patent number: 11767566Abstract: The present invention relates to a method for the in vitro detection of a latent tuberculosis infection (LTBI) in a subject, wherein said method comprises determining at least one nucleotide sequence and/or at least one polypeptide of Mycobacterium tuberculosis (Mtb) in a blood cell population of said subject, and wherein the presence of said at least one nucleotide sequence and/or said at least one polypeptide is indicative for said latent tuberculosis infection. In particular, the blood cell population is enriched for hematopoietic stem cells. The invention also relates to a pharmaceutical composition for use in the treatment of the LTBI in the subject, wherein it is determined if the nucleotide sequence and/or the polypeptide of Mtb is/are present in the blood cell population. Further, the invention relates to kits for carrying out the methods of the invention. The invention also relates to the use of the kits.Type: GrantFiled: June 6, 2017Date of Patent: September 26, 2023Assignees: Max-Planck-Gesellschaft, Medizinische Universität WienInventors: Julia Tornack, Stephen Reece, Fritz Melchers, Stefan H. E. Kaufmann, Wolfgang Bauer, Georg Stingl
-
Patent number: 11738077Abstract: The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.Type: GrantFiled: October 12, 2020Date of Patent: August 29, 2023Inventors: Jeremy Kroll, Mike Roof
-
Patent number: 11718648Abstract: Disclosed are immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cells.Type: GrantFiled: January 5, 2018Date of Patent: August 8, 2023Assignee: Evaxion Biotech A/SInventors: Niels Iversen Møller, Andreas Holm Mattsson
-
Patent number: 11707510Abstract: The invention relates to a botulinum neurotoxin-encoding nucleic acid for therapeutic use. The invention further relates to the transfection of skeletal muscle cells and smooth muscle cells and the glands of the skin, and of other skin cells with botulinum neurotoxin (BoNT)-encoding nucleic acids (RNA or DNA) with or without the use of a secretory signal, for therapeutic and/or cosmetic purposes.Type: GrantFiled: February 18, 2019Date of Patent: July 25, 2023Assignee: PRECLINICS DISCOVERY GMBHInventor: Jonas Füner
-
Patent number: 11697686Abstract: The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells. An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDP (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.Type: GrantFiled: October 28, 2020Date of Patent: July 11, 2023Assignees: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Satoshi Takagi, Yumiko Kagawa, Yasuhiko Suzuki, Chie Nakajima
-
Patent number: 11690899Abstract: The present invention relates to the field of medicine, specifically the field of bacterial infection and treatment thereof.Type: GrantFiled: March 10, 2016Date of Patent: July 4, 2023Assignee: Micreos Human Health B.V.Inventor: Fritz Eichenseher
-
Patent number: 11680296Abstract: Gene expression signatures and pathways associated with tuberculosis are identified. The invention provides for diagnostic assays based on gene markers and cell composition, as well as therapeutic targets for modulating tuberculosis infection. In addition, tuberculosis copy number contained in cells and methods of detecting high and low copy number are disclosed.Type: GrantFiled: October 16, 2018Date of Patent: June 20, 2023Assignee: Massachusetts Institute of TechnologyInventors: Alexander K. Shalek, Carly Ziegler
-
Patent number: 11679136Abstract: The present invention provides a composition comprising a co-culture of at least two distinct bacterial families, having differing growth and/or proliferative conditions. In some embodiments, the composition comprises a plurality of bacterial genera with high similarity to microbial flora.Type: GrantFiled: July 6, 2021Date of Patent: June 20, 2023Assignee: MYBIOTICS PHARMA LTD.Inventors: David Baram, David Daboush, Rachel Diamant